Einloggen

Thematische Bibliographien / Insulin-like growth factor I Physiology

Auswahl der wissenschaftlichen Literatur zum Thema „Insulin-like growth factor I Physiology“

Autor: Grafiati

Veröffentlicht am 4. Juni 2021

Zuletzt aktualisiert am 28. Januar 2023

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Insulin-like growth factor I Physiology" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Inhaltsverzeichnis

Zeitschriftenartikel
Dissertationen
Bücher
Buchteile
Konferenzberichte
Berichte der Organisationen

Zeitschriftenartikel zum Thema "Insulin-like growth factor I Physiology":

1

Holly, Jeff M. P., und Claire M. Perks. „Insulin-Like Growth Factor Physiology“. Endocrinology and Metabolism Clinics of North America 41, Nr. 2 (Juni 2012): 249–63. http://dx.doi.org/10.1016/j.ecl.2012.04.009.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Yakar, Shoshana, und Martin L. Adamo. „Insulin-Like Growth Factor 1 Physiology“. Endocrinology and Metabolism Clinics of North America 41, Nr. 2 (Juni 2012): 231–47. http://dx.doi.org/10.1016/j.ecl.2012.04.008.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Rosen, Clifford J. „Serum Insulin-like Growth Factors and Insulin-like Growth Factor-binding Proteins: Clinical Implications“. Clinical Chemistry 45, Nr. 8 (01.08.1999): 1384–90. http://dx.doi.org/10.1093/clinchem/45.8.1384.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Annotation:

Abstract The last decade has been characterized by a major investigative thrust into the physiology of two unique but ubiquitous peptides, insulin-like growth factor (IGF)-I and IGF-II. The regulatory systems that control the tissue bioactivity of the IGFs have been delineated, and subcellular signaling mechanisms have been clarified. Clearly, both tissue and circulating growth factor concentrations are important in defining the relationship between IGF-I and cell activity. Bone, liver, and circulatory IGF-I have received the most attention by investigators, in part because of the ease of measurement and the interaction with disease states such as osteoporosis. More recently, attention has focused on the role IGF-I plays in neoplastic transformation and growth. Two large prospective observational studies have demonstrated greater risk for prostate and breast cancer associated with high circulating concentrations of IGF-I. Animal models and in vitro studies confirm that there is a close, albeit complex, interaction between IGF-I signaling and bone turnover. This report will focus on: (a) IGF physiology, including IGF ligands, binding proteins, and proteases; (b) the relationship between IGF-I and bone mass in respect to risk for osteoporosis; (c) the heritable regulation of the IGF-I phenotype; and (d) the association between serum IGF-I and cancer risk. The IGFs remain a major area for basic and clinical investigations; future studies may define both diagnostic and therapeutic roles for these peptides or their related proteins in several disease states.

4

Pollak, Michael. „Insulin-like growth factor physiology and neoplasia“. Growth Hormone & IGF Research 10 (Januar 2000): S6—S7. http://dx.doi.org/10.1016/s1096-6374(00)90002-9.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Holly, Jeff M. P., Claire M. Perks und Claire E. H. Stewart. „Overview of insulin-like growth factor physiology“. Growth Hormone & IGF Research 10 (Januar 2000): S8—S9. http://dx.doi.org/10.1016/s1096-6374(00)90003-0.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Roith, Derek Le. „The Insulin-Like Growth Factor System“. Experimental Diabesity Research 4, Nr. 4 (2003): 205–12. http://dx.doi.org/10.1155/edr.2003.205.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Annotation:

The insulin-like growth factor (IGF) system in ubiquitous and plays a role in every tissue of the body. It is comprised of ligands, receptors and binding proteins, each with specific functions. While it plays an essential role in embryonic and post-natal development, the IGF system is also important in normal adult physiology. There are now numerous examples of diseases such as diabetes, cancer, and malnutrition in which the IGF system is a major player and, not surprisingly, there are attempts to affect these disorders by manipulating the system.

7

Pollak, M. „Insulin-like growth factor physiology and cancer risk“. European Journal of Cancer 36, Nr. 10 (Juni 2000): 1224–28. http://dx.doi.org/10.1016/s0959-8049(00)00102-7.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Gabbitas, Bari, und Ernesto Canalis. „Insulin-like growth factors sustain insulin-like growth factor-binding protein-5 expression in osteoblasts“. American Journal of Physiology-Endocrinology and Metabolism 275, Nr. 2 (01.08.1998): E222—E228. http://dx.doi.org/10.1152/ajpendo.1998.275.2.e222.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Annotation:

Insulin-like growth factors (IGFs) I and II are considered to be autocrine regulators of bone cell function. Recently, we demonstrated that IGF-I induces IGF-binding protein-5 (IGFBP-5) expression in cultures of osteoblast-enriched cells from 22-day fetal rat calvariae (Ob cells). In the present study, we postulated that IGFs play an autocrine role in the maintenance of IGFBP-5 basal expression in Ob cells. IGFBP-2 and -3, at concentrations that bind endogenous IGFs, decreased IGFBP-5 mRNA levels, as determined by Northern blot analysis, and protein levels, as determined by Western immunoblots of extracellular matrix extracts of Ob cells. IGFBP-2 and -3 in excess inhibited IGFBP-5 heterogeneous nuclear RNA levels, as determined by RT-PCR, and did not alter the half-life of IGFBP-5 mRNA in transcriptionally arrested Ob cells. In conclusion, blocking endogenous IGFs in Ob cells represses IGFBP-5 expression, suggesting that IGFs are autocrine inducers of IGFBP-5 synthesis in osteoblasts.

9

Sheppard, M. S., und R. M. Bala. „Insulin-like growth factor inhibition of growth hormone secretion“. Canadian Journal of Physiology and Pharmacology 64, Nr. 5 (01.05.1986): 525–30. http://dx.doi.org/10.1139/y86-087.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Annotation:

Somatomedins – insulin-like growth factors (SM/IGF) are growth hormone (GH) dependent serum growth factors. There is some evidence that IGF inhibit GH release (negative feedback) in 3- to 24-h incubations of cultured rat adenohypophysial cells. We have used acutely dispersed noncultured rat adenohypophysial cells to study the dynamics of IGF on GH secretion. In this system both IGF-I and IGF-II (100 ng/mL) slightly, but significantly, decrease the cumulative GH released by human pancreas growth hormone releasing factor 1–40 (GRF) and the phosphodiesterase inhibitor 3-isobutyl-1-methyl xanthine. The inhibition is small (16%) and usually not statistically significant until 2 h of incubation. The inhibition with IGF is additive to that produced with low concentrations of somatostatin. The IGF also sigificantly decrease the rate of GH release in all time periods tested (0–1, 1–2, 2–3 h). In addition, the IGF decrease the quantity of [14C]leucine protein eluted at the position of labelled rat GH on Sephadex G75, which would include newly synthesized GH extracted from the cells. Thus we conclude that the decreased GH released may be due to an effect of IGF on both rate of release and on GH synthesis.

10

Sowers, James R. „Insulin and Insulin-Like Growth Factor in Normal and Pathological Cardiovascular Physiology“. Hypertension 29, Nr. 3 (März 1997): 691–99. http://dx.doi.org/10.1161/01.hyp.29.3.691.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Mehr Quellen

Dissertationen zum Thema "Insulin-like growth factor I Physiology":

1

Burns, Jason Lee. „Growth control by insulin-like growth factor II“. Thesis, University of Oxford, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.270285.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Robertson, James Gray. „Insulin-like growth factors and insulin-like growth factor binding proteins in wounds /“. Title page, contents and abstract only, 1999. http://web4.library.adelaide.edu.au/theses/09PH/09phr6509.pdf.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Levitt, Randy J. „Aspects of insulin-like growth factor physiology in cancer“. Thesis, McGill University, 2006. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=111826.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Annotation:

The insulin-like growth factor (IGF) pathway consists of two ligands (IGF-I and IGF-II), two receptors (IGF-IR and IGF-IIR) and six IGF binding proteins (IGFBP-I through -6). There is considerable evidence from both laboratory and population studies that IGF physiology is relevant to neoplastic growth. For example, it has been shown that IGF-I and/or IGF-II act as mitogens and anti-apoptotic agents for both normal and malignant cells by binding to the IGF-IR and activating downstream signalling pathways. Consistent with this data, IGF-IR inhibition by a variety of strategies inhibits cancer cell proliferation and/or induces apoptosis both in vitro and in animal models of neoplasia. Furthermore, epidemiological studies have demonstrated a positive correlation between serum IGF-I levels and risk of subsequent cancer. Classically, the IGFBPs were considered to be growth inhibitors, as they had a well-defined role in sequestering the mitogens IGF-I and IGF-II, therefore preventing binding and subsequent activation of mitogenic and anti-apoptotic pathways downstream of the IGF-IR. However, increasing evidence indicates that under certain conditions, IGFBPs can act as growth stimulators, and both IGF-dependent and -independent mechanisms have been proposed.
Although the roles of the IGFs, IGF-IR and IGFBPs in cancer have been studied extensively, this thesis describes several new links between IGF physiology and neoplasia. In the first section, we demonstrate that IGF-I can attenuate growth inhibition and apoptosis induced by a class of drugs called COX-2 inhibitors in BxPC-3 pancreatic cancer cells. This effect could be attributed to opposite influences of IGF-IR signalling and COX-2 inhibitors on activation of Akt, with IGF-IR signalling increasing activity and COX-2 inhibitors decreasing activity. In the second section, we demonstrate that in 184htert cells, an immortal but untransformed breast epithelial cell line, COX-2 inhibitors can induce IGFBP-3 expression. We go on to show that IGFBP-3 can inhibit growth of this cell line in an IGF-dependent manner, and speculate that this action of COX-2 inhibitors may be relevant to data linking use of this class of drugs to decreased breast cancer risk. In the third section, we demonstrate that the expression of IGFBP-2 in U251 glioma cells is inhibited by the induction of the tumor suppressor PTEN. Furthermore, IGFBP-2 does not effect the growth of this cell line, indicating that published associations between tumor IGFBP-2 expression and grade of glioma may be a result of IGFBP-2 acting as a marker for loss of function of PTEN. In the fourth and final section, we demonstrate that in MDA-MB-231 breast cancer cells, over-expression of IGFBP-2 can enhance growth, indicating that the effect of IGFBP-2 on growth of neoplastic cells is tissue specific. Furthermore, antisense strategies targeting IGFBP-2 mRNA (antisense oligonucleotides and siRNA) can inhibit growth of IGFBP-2-expressing breast cancer cells both in vitro and in vivo.
Taken together, these results extend the existing body of evidence demonstrating that IGF physiology contributes to neoplastic growth, and suggest that strategies to inhibit IGF-IR signalling and/or IGFBP-2 expression may have therapeutic value for some types of cancers.

4

Bibollet-Bahena, Olivia. „The insulin-like growth factor-1 stimulates protein synthesis in oligodendrocyte progenitors /“. Thesis, McGill University, 2007. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=112382.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Annotation:

Insulin-like growth factor-1 (IGF-1) is essential for oligodendrocyte (OL) development, promoting their survival, proliferation and differentiation. Furthermore, IGF-1 null mutant mice have a decrease in CNS myelination and in the number of OL progenitors (OLPs). IGF-1 interacts with the Type I IGF receptor to activate two main downstream signalling pathways, the PI3K/Akt and the Ras-Raf-MEK/ERK cascades, which mediate survival or proliferation of OLPs. The objective of this study is to elucidate the transduction pathways involved in IGF-I-stimulated protein synthesis, important for growth and differentiation of OLs. In other cellular systems, the PI3K/Akt pathway is involved in protein translation. mTOR and the p70 S6 kinase are downstream effectors that phosphorylate translation initiation factors (e.g. eIF-4E) and their regulators (e.g. 4E-BP1). OLPs were obtained from primary cultures and were treated with IGF-1 with or without inhibitors LY294002 or wortmannin (PI3K), rapamycin (mTOR), Akt III or IV, an adenovirus with a dominant negative form of Akt or PD98059 (ERK). Protein synthesis was assessed by metabolic labeling with [35S]-methionine, and protein phosphorylation by Western blotting. Results from the former showed that IGF-1 stimulates protein synthesis in a dose-dependent manner. Moreover, IGF-1 increases protein synthesis in OLPs through PI3K, mTOR, Akt and ERK activation. Concordantly, Western blot analysis reveals that IGF-1 stimulates phosphorylation of Akt, mTOR, ERK, S6 and 4E-BP 1. Activation of S6 and inactivation of 4E-BP1 occur through phosphorylation and are required for protein synthesis to take place. These events are dependent on the upstream activation of PI3K, Akt and mTOR.

5

Robertson, Katherine. „The role of the growth hormone/IGF-I system on islet cell growth and insulin action /“. Thesis, McGill University, 2007. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=103288.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Annotation:

The study of diabetes mellitus is vital in this day and age because its incidence is increasing at an alarming rate. Diabetes results in the loss of function of beta-cells within the pancreas. Insulin resistance contributes to diabetes but the human body can compensate in various ways such as increasing the islet cell mass, glucose disposal and insulin secretion, in order to prevent the onset of diabetes. Growth hormone (GH) and insulin-like growth factor-I (IGF-I) are two integral hormones important in both glucose homeostasis and islet cell growth. Early studies using cultured islet cells have demonstrated positive regulation of beta-cell growth by both GH and IGF-I. To evaluate their relevance on normal beta-cell growth, compensatory growth, as well as in insulin responsiveness, we have used two mouse models that represent opposite manipulations of the GH/IGF-I axis. Specifically, the growth hormone receptor gene deficient (GHR-/-) and the IGF-I overexpression (MT-IGF) mice, to help understand the role of glucose homeostasis and islet cell growth in the GH/IGF-I axis. GH is essential for somatic growth and development as well as maintaining metabolic homeostasis. It is known that GH stimulates normal islet cell growth. Moreover, GH may also participate in islet cell overgrowth and compensate for insulin resistance induced by obesity. To determine whether the islet cell overgrowth is dependent on GH signaling, we studied the response of GHR-/- mice to high-fat diet (HFD)-induced obesity. We also studied the insulin responsiveness in GHR-/- mice. On the other hand, IGF-I promotes embryonic development, postnatal growth and the maturation of various organ systems. The notion that IGF-I stimulates islet cell growth has been challenged in recent years by results from IGF-I and receptor gene targeted models. We have characterized MT-IGF mice which overexpress the IGF-I gene.
The results of our studies indicate that (1) GH is essential for normal islet cell growth, but not required for compensatory overgrowth of the islets in response to obesity, (2) GHR gene deficiency caused delayed insulin responsiveness in skeletal muscle; in contrast to elevated insulin sensitivity in the liver; (3) although overexpression does not stimulate islet cell growth, a chronic IGF-I elevation caused significant hypoglycemia, hypoinsulinemia, and improved glucose tolerance, (4) finally IGF-I overexpression mice are resistant to experimental diabetes.

6

Kallincos, Nicholas Campbell. „Growth hormone (GH) and insulin-like growth factor-I (IGF-I) in vivo: investigation via transgenesis in rats“. Thesis, Adelaide, 1993. http://hdl.handle.net/2440/21602.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Kallincos, Nicholas Campbell. „Growth hormone (GH) and insulin-like growth factor-I (IGF-I) in vivo: investigation via transgenesis in rats /“. Adelaide : Thesis (Ph.D.) -- University of Adelaide, Department of Biochemistry, 1993. http://web4.library.adelaide.edu.au/theses/09PH/09phk143.pdf.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Lu, Yarong 1971. „Pancreatic-specific insulin-like growth factor I gene deficiency on islet cell growth and protection“. Thesis, McGill University, 2006. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=111827.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Annotation:

The role of insulin-like growth factor I (IGF-I) in pancreatic islet cell growth and development has been debated in recent years. The dogma that IGF-I stimulates pancreatic islet growth has been challenged by combinational targeting of IGF or IGF-IR genes, as well as beta-cell-specific IGF-IR gene deficiency. In order to assess the physiological role of locally produced IGF-I, we have developed pancreatic-specific IGF-I gene deficiency (PID) by crossing Pdx1-Cre and IGF-I/loxP mice. PID mice were normal except for decreased blood glucose level and a 2.3-fold enlarged islet cell mass. When challenged with low doses of streptozotocin, control mice developed hyperglycemia after 6 days that was maintained at high levels for at least 2 months. In contrast, PID mice only exhibited marginal hyperglycemia after 12 days, maintained throughout the experiment. Furthermore, streptozotocin-induced beta-cell apoptosis (TUNEL assay) was significantly prevented in PID mice. PID mice also exhibited a delayed onset of type 2 diabetes induced by a high-fat diet, accompanied by super enlarged pancreatic islets and preserved sensitivity to insulin. As the phenotype is unlikely a direct consequence of IGF-I deficiency, we used oligonucleotide DNA microarray to explore possible activation of pro-islet genes in PID mice, which revealed upregulation of multiple new members of the Reg family genes (Reg2, 3alpha and 3beta) in the pancreas. The results were subsequently confirmed by Northern blot and/or realtime PCR, which exhibited 2 to 8 fold increases in the level of their mRNAs. Moreover, these Reg family genes were also activated following streptozotocin-induced beta-cell damage and diabetes. Our results reveal a possible mechanism of islet growth and protection in PID mice, thus serving a potential strategy in combating diabetes.

9

Lok, Fong. „Role of IGF-I in ovine fetal and placental growth and development /“. Title page, contents and abstract only, 1998. http://web4.library.adelaide.edu.au/theses/09PH/09phl836.pdf.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Kind, Karen Lee. „Insulin-like growth factors and growth of the fetal sheep /“. Title page, contents and abstract only, 1995. http://web4.library.adelaide.edu.au/theses/09PH/09phk525.pdf.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Mehr Quellen

Bücher zum Thema "Insulin-like growth factor I Physiology":

1

1945-, LeRoith Derek, Hrsg. Insulin-like growth factors: Molecular and cellular aspects. Boca Raton: CRC Press, 1991.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Jr, Roberts Charles T., und Rosenfeld Ron G, Hrsg. The IGF system: Molecular biology, physiology, and clinical applications. Totowa, N.J: Humana Press, 1999.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

International Symposium on Molecular and Cellular Biology of Insulin and IGFs (3rd 1990 Gainesville, Fla.). Molecular biology and physiology of insulin and insulin-like growth factors. New York: Plenum Press, 1991.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

1945-, LeRoith Derek, Raizada Mohan K und International Symposium on Insulin, IGFs, and their Receptors (4th : 1993 : Woods Hole, Mass.), Hrsg. Current directions in insulin-like growth factor research. New York: Plenum, 1993.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Raizada, Mohan K., und Derek LeRoith, Hrsg. Molecular Biology and Physiology of Insulin and Insulin-Like Growth Factors. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4684-5949-4.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Raizada, Mohan K. Molecular Biology and Physiology of Insulin and Insulin-Like Growth Factors. Boston, MA: Springer US, 1991.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Hooghe-Peters, Elisabeth. Growth hormone, prolactin, and IGF-1 as lymphohemopoietic cytokines. New York: Springer-Verlag, 1995.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Hooghe-Peters, Elisabeth L. Growth hormone, prolactin, and IGF-1 as lymphohemopoietic cytokines. Austin: R.G. Landes, 1995.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

International Symposium on Insulin-Like Growth Factors/Somatomedins (2nd 1991 San Francisco, Calif.). Modern concepts of insulin-like growth factors: Proceedings of the Second International Symposium on Insulin-Like Growth Factors/Somatomedins held January 12-16, 1991 in San Francisco, California. New York: Elsevier, 1991.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

International Symposium on Insulin-Like Growth Factors (3rd 1994 Sydney, N.S.W.). The insulin-like growth factors and their regulatory proteins: Proceedings of the Third International Symposium on Insulin-Like Growth Factors, Sydney, 6-10 February 1994. Herausgegeben von Baxter R. C, Gluckman Peter D und Rosenfeld Ron G. Amsterdam: Excerpta Medica, 1994.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Mehr Quellen

Buchteile zum Thema "Insulin-like growth factor I Physiology":

1

Aguirre, Gabriel A., José Luis González-Guerra, Luis Espinosa und Inma Castilla-Cortazar. „Insulin-Like Growth Factor 1 in the Cardiovascular System“. In Reviews of Physiology, Biochemistry and Pharmacology, Vol. 175, 1–45. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/112_2017_8.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Adashi, Eli Y., Carol Resnick, Eleuterio R. Hernandez, Marjorie E. Svoboda, E. Hoyt, David R. Clemmons, Pauline K. Lund und Judson J. Van Wyk. „Rodent Studies on the Potential Relevance of Insulin-Like Growth Factor (IGF-I) to Ovarian Physiology“. In Growth Factors and the Ovary, 95–105. Boston, MA: Springer US, 1989. http://dx.doi.org/10.1007/978-1-4684-5688-2_7.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Frohman, Lawrence A. „Physiology of the Growth Hormone Releasing Hormone-Somatostatin-Growth Hormone-Insulin-Like Growth Factor I Axis“. In GHRH, GH, and IGF-I, 3–10. New York, NY: Springer New York, 1995. http://dx.doi.org/10.1007/978-1-4612-0807-5_1.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Martín-Estal, I., R. G. de la Garza und I. Castilla-Cortázar. „Intrauterine Growth Retardation (IUGR) as a Novel Condition of Insulin-Like Growth Factor-1 (IGF-1) Deficiency“. In Reviews of Physiology, Biochemistry and Pharmacology, 1–35. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/112_2015_5001.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Froesch, E. R. „Insulin-like Growth Factor: Endocrine and Autocrine/Paracrine Implications and Relations to Diabetes Mellitus“. In Contributions of Physiology to the Understanding of Diabetes, 127–47. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60475-1_9.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Martín-Estal, I., R. G. de la Garza und I. Castilla-Cortázar. „Erratum to: Intrauterine Growth Retardation (IUGR) as a Novel Condition of Insulin-Like Growth Factor-1 (IGF-1) Deficiency“. In Reviews of Physiology, Biochemistry and Pharmacology, 129. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/112_2016_1.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Moolenaar, W. H., K. Jalink und E. J. van Corven. „Lysophosphatidic acid: A bioactive phospholipid with growth factor-like properties“. In Reviews of Physiology, Biochemistry and Pharmacology, 47–65. Berlin, Heidelberg: Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/3540551921_3.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Jacobs, S. „Insulin-like Growth Factor I Receptors“. In Insulin, 267–86. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74098-5_13.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

Seth, John. „Insulin-Like Growth Factor-I“. In The Immunoassay Kit Directory, 197–203. Dordrecht: Springer Netherlands, 1994. http://dx.doi.org/10.1007/978-94-011-1414-1_29.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Seth, John. „Insulin-Like Growth Factor-II“. In The Immunoassay Kit Directory, 204–5. Dordrecht: Springer Netherlands, 1994. http://dx.doi.org/10.1007/978-94-011-1414-1_30.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Konferenzberichte zum Thema "Insulin-like growth factor I Physiology":

1

Wijayanti, Dian, Sunarjati Sudigdo Adi, Achadiyani, Gaga Irawan Nugraha, Reni Farenia und Adi Santosa Maliki. „The Effect of Intermitten Fasting Vs Low Calorie Diet to Insuline Like Growth Factor-1 (IGF-1) Concentration, Fat Mass and Lean Mass of Rattus Norvegicus Obesity Model“. In Surabaya International Physiology Seminar. SCITEPRESS - Science and Technology Publications, 2017. http://dx.doi.org/10.5220/0007332600530055.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Yerushalmi, R., B. Gilks, T. Nielsen, S. Leang, M. Cheang, R. Woods, K. Gelmon und H. Kennecke. „Insulin like growth factor in breast cancer subtypes.“ In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-3048.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Doyle, Suzanne L., Claire Donohoe, Joanne Lysaght, Fiona Lithander, Graham Pidgeon und John V. Reynolds. „Abstract 2283: The role of insulin-like growth factor-1 and insulin like growth factor-1 receptor in obesity and oesophageal cancer“. In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-2283.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Rice, Megan S., Rulla M. Tamimi, James L. Connolly, Laura C. Collins, Dejun Shen, Michael N. Pollak, Bernard Rosner, Susan E. Hankinson und Shelley S. Tworoger. „Abstract A68: Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and lobule type in the Nurses' Health Study II“. In Abstracts: AACR International Conference on Frontiers in Cancer Prevention Research‐‐ Oct 22-25, 2011; Boston, MA. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1940-6207.prev-11-a68.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Nedelkov, Dobrin, Eric Niederkofler, David Phillips, Bryan Krastins, Urban Kiernan, Kemmons Tubbs und Mary Lopez. „Abstract 2508: Mass spectrometric immunoassay for insulin-like growth factor 1.“ In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-2508.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Warnken, M., U. Reitzenstein, M. Fuhrmann, P. Mayer, H. Enzmann und K. Racke. „Characterization of Proliferative Effects of Insulin and Insulin-Like Growth Factor in Human Airway Epithelial Cells.“ In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a4982.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Yee, Douglas, Dedra H. Fagan, Xihong Zhang, Annabell S. Oh, Kelly LaPara, Marc Becker, Deepali Sachdev und Hua Zhang. „Abstract CN07-02: Disrupting insulin‐like growth factor signaling with monoclonal antibodies“. In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 15-19, 2009; Boston, MA. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/1535-7163.targ-09-cn07-02.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Fritton, J. Christopher, Yuki Kawashima, Hui Sun, Yingjie Wu, Wilson Mejia, Hayden W. Courtland, Clifford J. Rosen und Shoshana Yakar. „Bone Marrow Adipogenesis Is Affected by Insulin-Like Growth Factor-1 Complexes“. In ASME 2009 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2009. http://dx.doi.org/10.1115/sbc2009-206158.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Annotation:

Fat tissue, which is composed of lipid-filled adipocytes that accumulate during aging, displaces mineralized tissue and reduces the mechanical integrity bone. Bone marrow adipocytes provide stroma for maintenance of mesencymal stem cells (MSC) and reside at sites of bone turnover (i.e., endosteal surfaces where osteoblasts form new bone), potentially influencing cell activity via a paracrine route.

9

Bruns, Alexander-Francisco, Jessica Smith, Pooja Shah, Nadira Yuldasheva, Mark T. Kearney und Stephen Wheatcroft. „145 Insulin-like growth factor binding protein 2 (igfbp2) positively regulates angiogenesis“. In British Cardiovascular Society Annual Conference ‘High Performing Teams’, 4–6 June 2018, Manchester, UK. BMJ Publishing Group Ltd and British Cardiovascular Society, 2018. http://dx.doi.org/10.1136/heartjnl-2018-bcs.141.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Ibrahim, YH, J. Hartel, K. La Parra und D. Yee. „Insulin-like growth factor binding protein-1 (IGFBP-1) targets both the insulin-like growth factor (IGF) and integrin pathways for the inhibition of breast cancer cell motility.“ In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-402.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Berichte der Organisationen zum Thema "Insulin-like growth factor I Physiology":

1

Gross, Jennifer M. Insulin-Like Growth Factor Binding Protein-1 Interacts with Integrins to Inhibit Insulin-Like Growth Factor-Induced Breast Cancer Growth and Migration. Fort Belvoir, VA: Defense Technical Information Center, Juli 2003. http://dx.doi.org/10.21236/ada420347.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Cleveland, Rebecca J., Marilie D. Gammon und Ralph S. Baric. Insulin-Like Growth Factor I Polymorphisms in Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, September 2002. http://dx.doi.org/10.21236/ada412654.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Morrison, Tiffany. The Regulation of Insulin-like Growth Factor 1 by Growth Hormone via Stat5b. Portland State University Library, Januar 2012. http://dx.doi.org/10.15760/honors.14.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Harbeson, Caroline E., und Steven A. Rosenzweig. The Role of Insulin-Like Growth Factor (IGF) in IGF-Mediated Tumorigenesis. Fort Belvoir, VA: Defense Technical Information Center, Juli 2004. http://dx.doi.org/10.21236/ada432027.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Jarrard, David F. Relaxation of Insulin-Like Growth Factor II Imprinting in Prostate Cancer Development. Fort Belvoir, VA: Defense Technical Information Center, Januar 2005. http://dx.doi.org/10.21236/ada433881.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Jarrard, David F. Relaxation of Insulin-Like Growth Factor II Imprinting in Prostate Cancer Development. Fort Belvoir, VA: Defense Technical Information Center, Januar 2003. http://dx.doi.org/10.21236/ada414797.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Jarrard, David F. Relaxation of Insulin-Like Growth Factor II Imprinting in Prostate Cancer Development. Fort Belvoir, VA: Defense Technical Information Center, Januar 2004. http://dx.doi.org/10.21236/ada423078.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Doughterty, Michele K. Insulin Like Growth Factor I Receptor Function in Estrogen Receptor Negative Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, Juli 2001. http://dx.doi.org/10.21236/ada396720.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

Bartucci, Monica, und Ewa Surmacz. Cell-Cell Adhesion and Insulin-Like Growth Factor I Receptor in Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, September 2001. http://dx.doi.org/10.21236/ada398204.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Dougherty, Michele K. Insulin Like Growth Factor 1 Receptor Function in Estrogen Receptor Negative Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, Juli 2002. http://dx.doi.org/10.21236/ada408990.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen